User login
BRUSSELS – Statin therapy may exert yet another beneficial clinical effect – preventing the development of knee osteoarthritis and slowing its progression – based on an analysis of more than 3,000 people who were enrolled in a prospective cohort study.
In an analysis of people in the Rotterdam Study, statin use was linked with a more-than-50% reduced rate of knee osteoarthritis (OA) incidence, and a more-than-50% reduced rate of knee OA progression after adjustment for baseline risk factors, Dr. Stefan Clockaerts said at the congress. In contrast, statin use had no impact on hip OA.
The findings suggest knee OA may be at least partly a metabolic disease, said Dr. Clockaerts of the orthopedics department at Erasmus University, Rotterdam, the Netherlands, and at the University of Antwerp (Belgium).
“We think that there is a difference in the pathogenesis of hip and knee osteoarthritis, and that several systemic factors – such as cholesterol, body mass index, and diabetes – appear to influence knee osteoarthritis” but not deterioration of the hip, Dr. Clockaerts said in an interview.
Another hypothesis is that vascular pathology may contribute to the OA disease process, and that statins' benefits on atherosclerosis may also link statins and knee OA. The anti-inflammatory effect of statins most likely also plays a role.
The Rotterdam Study began in 1990 and enrolled 7,983 men and women aged 55 years or older into a longitudinal cohort study. The analysis by Dr. Clockaerts and his associates focused on participants with knee and hip x-rays that were available from baseline and follow-up and were evaluable for scoring on the Kellgren-Lawrence (KL) scale.
Information on statin use came from computerized pharmacy records. The analysis considered anyone to be a statin user who received a statin prescription for at least 100 days for at least 50% of the drug's recommended daily dosage.
Among 3,056 people who were evaluable for incident knee OA, statin users had a significant, 57% reduced rate of knee OA, vs. nonusers, after adjustment for baseline age, diabetes, BMI, total cholesterol:HDL cholesterol ratio, and bone mineral density (BMD), said Dr. Clockaerts at the congress, which was presented by the Osteoarthritis Research Society International. (See box.)
Progression of knee OA among 1,412 people with a baseline KL score of 1-3 occurred 53% less often in the statin users, compared with nonusers after adjustment for age, BMI, and BMD, which was a significant difference.
Dr. Clockaerts said that he had no disclosures.
Elsevier Global Medical News
BRUSSELS – Statin therapy may exert yet another beneficial clinical effect – preventing the development of knee osteoarthritis and slowing its progression – based on an analysis of more than 3,000 people who were enrolled in a prospective cohort study.
In an analysis of people in the Rotterdam Study, statin use was linked with a more-than-50% reduced rate of knee osteoarthritis (OA) incidence, and a more-than-50% reduced rate of knee OA progression after adjustment for baseline risk factors, Dr. Stefan Clockaerts said at the congress. In contrast, statin use had no impact on hip OA.
The findings suggest knee OA may be at least partly a metabolic disease, said Dr. Clockaerts of the orthopedics department at Erasmus University, Rotterdam, the Netherlands, and at the University of Antwerp (Belgium).
“We think that there is a difference in the pathogenesis of hip and knee osteoarthritis, and that several systemic factors – such as cholesterol, body mass index, and diabetes – appear to influence knee osteoarthritis” but not deterioration of the hip, Dr. Clockaerts said in an interview.
Another hypothesis is that vascular pathology may contribute to the OA disease process, and that statins' benefits on atherosclerosis may also link statins and knee OA. The anti-inflammatory effect of statins most likely also plays a role.
The Rotterdam Study began in 1990 and enrolled 7,983 men and women aged 55 years or older into a longitudinal cohort study. The analysis by Dr. Clockaerts and his associates focused on participants with knee and hip x-rays that were available from baseline and follow-up and were evaluable for scoring on the Kellgren-Lawrence (KL) scale.
Information on statin use came from computerized pharmacy records. The analysis considered anyone to be a statin user who received a statin prescription for at least 100 days for at least 50% of the drug's recommended daily dosage.
Among 3,056 people who were evaluable for incident knee OA, statin users had a significant, 57% reduced rate of knee OA, vs. nonusers, after adjustment for baseline age, diabetes, BMI, total cholesterol:HDL cholesterol ratio, and bone mineral density (BMD), said Dr. Clockaerts at the congress, which was presented by the Osteoarthritis Research Society International. (See box.)
Progression of knee OA among 1,412 people with a baseline KL score of 1-3 occurred 53% less often in the statin users, compared with nonusers after adjustment for age, BMI, and BMD, which was a significant difference.
Dr. Clockaerts said that he had no disclosures.
Elsevier Global Medical News
BRUSSELS – Statin therapy may exert yet another beneficial clinical effect – preventing the development of knee osteoarthritis and slowing its progression – based on an analysis of more than 3,000 people who were enrolled in a prospective cohort study.
In an analysis of people in the Rotterdam Study, statin use was linked with a more-than-50% reduced rate of knee osteoarthritis (OA) incidence, and a more-than-50% reduced rate of knee OA progression after adjustment for baseline risk factors, Dr. Stefan Clockaerts said at the congress. In contrast, statin use had no impact on hip OA.
The findings suggest knee OA may be at least partly a metabolic disease, said Dr. Clockaerts of the orthopedics department at Erasmus University, Rotterdam, the Netherlands, and at the University of Antwerp (Belgium).
“We think that there is a difference in the pathogenesis of hip and knee osteoarthritis, and that several systemic factors – such as cholesterol, body mass index, and diabetes – appear to influence knee osteoarthritis” but not deterioration of the hip, Dr. Clockaerts said in an interview.
Another hypothesis is that vascular pathology may contribute to the OA disease process, and that statins' benefits on atherosclerosis may also link statins and knee OA. The anti-inflammatory effect of statins most likely also plays a role.
The Rotterdam Study began in 1990 and enrolled 7,983 men and women aged 55 years or older into a longitudinal cohort study. The analysis by Dr. Clockaerts and his associates focused on participants with knee and hip x-rays that were available from baseline and follow-up and were evaluable for scoring on the Kellgren-Lawrence (KL) scale.
Information on statin use came from computerized pharmacy records. The analysis considered anyone to be a statin user who received a statin prescription for at least 100 days for at least 50% of the drug's recommended daily dosage.
Among 3,056 people who were evaluable for incident knee OA, statin users had a significant, 57% reduced rate of knee OA, vs. nonusers, after adjustment for baseline age, diabetes, BMI, total cholesterol:HDL cholesterol ratio, and bone mineral density (BMD), said Dr. Clockaerts at the congress, which was presented by the Osteoarthritis Research Society International. (See box.)
Progression of knee OA among 1,412 people with a baseline KL score of 1-3 occurred 53% less often in the statin users, compared with nonusers after adjustment for age, BMI, and BMD, which was a significant difference.
Dr. Clockaerts said that he had no disclosures.
Elsevier Global Medical News